Novo Nordisk A/S Will Build $100 Million Facility In Denmark
Novo Nordisk isn't the only one hiring, others are hiring too! Check it out! Novo Nordisk has said it plans to build a new purification plant at its R&D facility in Bagsvaerd, Denmark, to support its diabetes pipeline.
Trending on the Topix Network
Novo Nordisk - An Opportune Time To Book Profits
NVO, which has so far dominated the diabetes market, is expected to face tough times as competition is growing fierce and strong and will unfavorably impact NVO share.
Wed Mar 12, 2014
Report Published: "Cellectis S.A. (ALCLS) - Pharmaceuticals &...
It specializes in the area of genome engineering and genomic surgery. Its activities focus on highly specific DNA engineering technologies.
Tue Mar 11, 2014
Eli Lilly - The 'Never Say Die' Pharmaceutical
Results of AWARD 6 trials establish shows once-weekly diabetes drug, Dulaglutide as good as same class Novo Nordisk drug, Victoza.
Caisson Biotech Expands HEPtunea Drug Delivery Deal with Novo Nordisk
This latest license agreement gives Novo Nordisk 1) exclusive rights to commercialize insulin conjugated to HEPtune and 2) non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as ... (more)
Mon Mar 10, 2014
The Motley Fool
Who Will Capture This $3.5 Billion Opportunity?
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's -- to pay Ophthotech $125 million up front and another $50 million in series C funding last May. That financing allowed Ophthotech to launch a phase 3 Fovista trial last fall.
Thu Mar 06, 2014
Mark Gareth Creasy to Acquire 11,646,047 Common Shares of Novo Resources Corp.
") have the right to the issuance of up to 11,646,047 common shares of Novo Resources Corp. representing approximately 17.3% of the issued and outstanding common shares of Novo taking into account the issuance of the said 11,646,047 common shares.
New Study Reveals Psychological Impact of Diabetes Extends beyond Patients to Family Members
Study results announced today by Novo Nordisk and collaborative partners at the Diabetes UK conference show psychological support should be a priority for diabetes care in the UK, alongside improved education and self-management of the condition.
Press release distribution, EDGAR filing, XBRL, regulatory filings
Ford China sales are up 59 percent so far this year, with sales of 167,506 vehicles compared to ... )--On March 4, Sony's Remote Control & TV Guide app "TV SideView" has conducted a full-scale renewal of the Android version offering three new experiences that change the way u... )--FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A ... (more)
Tue Mar 04, 2014
Novo Knocks it Out of the Park with New "Echo" Smart Insulin Pen
My first response is to glare at her. I'm 50 years old fer' God's sake. I don't need to be reminded to take my insulin.
Novo Nordisk A/S Dumps Cash Into Pakistan
Novo Nordisk is investing in numerous training and education programmes to improve diabetes awareness in Pakistan, a statement said.
Mon Mar 03, 2014
GLP-1 Race In Diabetes: Eli Lilly Vs. Competitors
In February Eli Lilly announced positive results from the sixth Award trial for the once-weekly experimental drug dulaglutide.
Novo Nordisk A/S - Share repurchase programme
On 30 January 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Sat Mar 01, 2014
Diabetes in Pakistan to Double by 2035
It is estimated that this number will rise to 12.8 million by 2035, which puts Pakistan among the top countries with the highest number of population suffering from diabetes.
Fri Feb 28, 2014
PIMS diabetic clinic upgraded
To meet the increasing burden of diabetic patients, Pakistan Institute of Medical Sciences has upgraded its Diabetic Foot Clinic to a full Diabetic Centre with the kind support of the Danish global pharma Novo Nordisk.
Thu Feb 27, 2014
The Story of Novo Nordisk's Environmental Profit and Loss Account
Novo Nordisk has become the first pharmaceutical company in the world to publish an Environmental Profit and Loss account.
Wed Feb 26, 2014
The New York Observer
Tough to Swallow: Paper Trail Behind 'Breakthrough' Leads to Penny-stock Profiteers
Let me get one thing straight: I was predisposed to cheer for Oramed Pharmaceuticals, a tiny Jerusalem-based drug developer that has been working on an orally ingested insulin pill for more than a decade.
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events.
Tue Feb 25, 2014
Novo Nordisk Stock Rating Upgraded by Bank of America
A number of other firms have also recently commented on NVO. Analysts at JPMorgan Chase & Co.
Novo Nordisk Adds Environmental P&L to Their Sustainable Toolset
It's an old management truism that says you can't manage what you can't measure.